Document is current
Any future updates will be listed below
-
Authors
Weiss, Karl Heinz
Kruse, Carlot
Abd-Elaziz, Khalid
van der Horst, Eric
Fu, ChauHwei
Aliane, Verena
Scherpbier, Jan-Jaap
Gerrits, Mireille
Dogterom, Peter
-
Funding
Funding for this research was provided by:
Univar Solutions BV
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 10 October 2025
First Online: 7 January 2026
Declarations
:
: K.H. Weiss advises for Univar Solutions BV, Vivet Therapeutics, Alexion, Orphalan, Ultragenyx, Pfizer, AbbVie, Bayer and is on the speakers bureau of Alexion, Orphalan and Falk and received travel support from Alexion. For the remaining authors, no conflict of interests were declared.
